Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1497239 | 0.79 | ALDH1A1 (0.49) | KDM4EKMT2ASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL27667909 | 0.78 | ADORA2B (0.46) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL6889649 | 0.72 | ADORA2B (0.69) | KDM4EKMT2ASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL6473698 | 0.67 | ADORA2B (0.52) | KDM4EKMT2ASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL3479031 | 0.67 | ADORA2B (0.67) | KDM4EKMT2AALDH1A1HSD17B10ADORA2A | |
| SCHEMBL1497265 | 0.66 | ALDH1A1 (0.44) | KDM4EKMT2ASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL22105782 | 0.66 | ADORA2B (0.54) | KDM4EALDH1A1HSD17B10ADORA2AADORA2B | |
| SCHEMBL23565377 | 0.65 | GAA (0.85) | KDM4EKMT2ASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL1944674 | 0.65 | ADORA2B (0.74) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL19012232 | 0.65 | DAO (0.50) | KDM4EKMT2ASMN1; SMN2ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | claimed |
| EP-1658291-A2 | SUBSTITUTED 8-HETEROARYL XANTHINES | Adenosine Therapeutics, LLC (US) | 2006-05-24 | — | — | EP | claimed |
| US-20050065341-A1 | Substituted 8-heteroaryl xanthines | ALLERGAN SALES, LLC | 2005-03-24 | — | — | US | claimed |
| WO-2005021548-A2 | SUBSTITUTED 8-HETEROARYL XANTHINES | ADENOSINE THERAPEUTICS, LLC (US) | 2005-03-10 | — | — | WO | claimed |
| EP-2295434-B1 | Substituted 8-heteroaryl xanthines | DOGWOOD PHARMACEUTICALS INC (US) | 2015-09-30 | — | — | EP | disclosed |
| EP-1658291-B1 | SUBSTITUTED 8-HETEROARYL XANTHINES | DOGWOOD PHARMACEUTICALS INC (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2295434-A2 | Substituted 8-heteroaryl xanthines | Adenosine Therapeutics, LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | PGXHEALTH, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-7732455-B2 | Substituted 8-heteroaryl xanthines | PGX HEALTH, LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1658291-A2 | SUBSTITUTED 8-HETEROARYL XANTHINES | Adenosine Therapeutics, LLC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20050065341-A1 | Substituted 8-heteroaryl xanthines | ALLERGAN SALES, LLC | 2005-03-24 | — | — | US | disclosed |
| WO-2005021548-A2 | SUBSTITUTED 8-HETEROARYL XANTHINES | ADENOSINE THERAPEUTICS, LLC (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ADORA2B, ADORA2A, ADORA3 | KDM4E 3207/4885KMT2A 1888/4885SMN1; SMN2 3702/4885 |
| US-20050065341-A1 | Substituted 8-heteroaryl xanthines | ADORA2B, ADORA2A, ADORA3 | KDM4E 3207/4885KMT2A 1888/4885SMN1; SMN2 3702/4885 |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | ADORA2B, ADORA2A, ADORA3 | KDM4E 3207/4885KMT2A 1888/4885SMN1; SMN2 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.